BACKGROUND Although few studies have reported hyponatremia due to carbamazepine or oxcarbazepine in patients with epilepsy,no study has investigated cases of carbamazepine-or oxcarbazepine-induced hyponatremia or unst...BACKGROUND Although few studies have reported hyponatremia due to carbamazepine or oxcarbazepine in patients with epilepsy,no study has investigated cases of carbamazepine-or oxcarbazepine-induced hyponatremia or unsteady gait in patients with neuropathic pain.Herein,we report a case of oxcarbazepineinduced lower leg weakness in a patient with trigeminal neuralgia and summarize the diagnosis,treatment,and changes of clinical symptoms.CASE SUMMARY A 78-year-old male with a history of lumbar spinal stenosis was admitted to the hospital after he experienced lancinating pain around his right cheek,eyes,and lip,and was diagnosed with trigeminal neuralgia at the right maxillary and mandibular branch.He was prescribed oxcarbazepine(600 mg/d),milnacipran(25 mg/d),and oxycodone/naloxone(20 mg/10 mg/d)for four years.Four years later,the patient experienced symptoms associated with spinal stenosis,including pain in the lower extremities and unsteady gait.His serum sodium level was 127 mmol/L.Assuming oxcarbazepine to be the cause of the hyponatremia,oxcarbazepine administration was put on hold and the patient was switched to topiramate.At subsequent visit,the patient’s serum sodium level had normalized to 143 mmol/L and his unsteady gait had improved.CONCLUSION Oxcarbazepine-induced hyponatremia may cause lower extremity weakness and unsteady gait,which should be differentiated from those caused by spinal stenosis.展开更多
Objective:To study effect of Oxcarbazepine on serum inflammatory factors, intercellular adhesion molecule 1(ICAM-1) and immune function in epileptic.Methods: Selected 95 patients who were diagnosed as epileptic into t...Objective:To study effect of Oxcarbazepine on serum inflammatory factors, intercellular adhesion molecule 1(ICAM-1) and immune function in epileptic.Methods: Selected 95 patients who were diagnosed as epileptic into the observation group and 95 cases of healthy people as the control group;The observation group was given oral oxcarbazepine, continuous treatment for six months;Measured serum inflammatory factors (IL-2, IL-6, TNF-α) level, ICAM-1 and immune-related indexes: change of periphery T lymphocyte subgroup CD3+, CD4+, CD8+and immnuneglublin (IgG, IgA, IgM) level of the observation group before and after treatment, carried out comparative analysis through comparing with the normal control group.Results:Before treatment, compared with the control group, level of IL-2, IL-6, TNF-α, ICAM-1, CD8+, IgA and IgG in observation group were significantly higher than those in control group. CD3+, CD4+ level were significantly decreased when it compared with the control group. Level of IgM in the observation group was higher than that in the control group, but the difference between two groups was not significant. Before treatment, compared inter-class, level of IL-2, IL-6, TNF-α, ICAM-1, CD8+, IgA and IgG in the observation group were significantly lower, but all of these indexes level were still remarkable higher than the control group. It was statistical significant difference;After treatment, the level of CD3+, CD4+ in the observation group were dramatically increased, but both level were still significantly lower than the control group, the difference was statistically significant;Level of IgM after treatment compared with control group and before treatment respectively was no statistical significant difference.Conclusion: The level of inflammatory factors and ICAM-1 always were abnormal in epileptic and they were always with immune dysfunction. Oxcarbazepine was capable of effectively reducing inflammatory factor and ICAM-1 level and positively regulating immune dysfunction.展开更多
Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May...Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May 2018 were selected as the observation group and 90 healthy volunteers were selected as control group. All patients in the observation group were treated with oxcarbazepine alone. T lymphocyte subsets, IgA, IgG, IgM, T3, T4, FT3, FT4, TSH, hs-CRP and Hcy in observation group were detected before treatment, 3 months after treatment and 6 months after treatment. The results were compared with those of the control group. Results: The levels of CD3+ and CD4+ in the control group were (65.25±9.51)% and (43.29±6.74)% respectively, which were higher than those in the observation group (P<0.05). The levels of CD8+, IgA and IgG in the control group were (22.40±6.41)%, (2.22±0.51) g/L, (9.99±1.28) g/L respectively, which were lower than those in the observation group (P<0.05). The levels of CD3+ and CD4+ in the observation group after 3 months and 6 months of treatment were significantly higher than those before treatment (P<0.05). The levels of CD8+, IgA and IgG in the observation group after 3 months and 6 months of treatment were significantly lower than those before treatment (P<0.05). There was no significant difference in the level of IgM between the observation group and the control group at each time point (P>0.05). The levels of thyroid hormones in the observation group before treatment and 3 months after treatment were not significantly different from those in the control group (P>0.05). The FT4 of the observation group was (14.98±1.03) pmol/L 6 months after treatment, which was significantly lower than that of the control group before treatment and 3 months after treatment (P<0.05). The levels of T3, T4, FT3 and TSH at each time point in the observation group were not significantly different from those in the control group (P>0.05). Before treatment, there was no significant difference in hs-CRP and Hcy levels between the observation group and the control group (P>0.05). The levels of hs-CRP and Hcy in the observation group were (4.82±0.67) mg/L and (13.36±1.51) umol/L respectively after 3 months of treatment. The levels of hs-CRP and Hcy in the observation group after 3 months of treatment were significantly higher than those before treatment and in the control group, and the difference was statistically significant (P<0.05). The levels of hs-CRP and Hcy in the observation group were (4.99±0.47) mg/L and (16.83±1.94) umol/L respectively after 6 months of treatment. The levels of hs-CRP and Hcy in the observation group were significantly higher than those in the control group after 3 months of treatment and before treatment (P<0.05). Conclusion: Oxcarbazepine can effectively improve the immune function of epilepsy patients, but with the prolongation of medication time, it may have adverse effects on thyroid function, hs-CRP and Hcy.展开更多
文摘BACKGROUND Although few studies have reported hyponatremia due to carbamazepine or oxcarbazepine in patients with epilepsy,no study has investigated cases of carbamazepine-or oxcarbazepine-induced hyponatremia or unsteady gait in patients with neuropathic pain.Herein,we report a case of oxcarbazepineinduced lower leg weakness in a patient with trigeminal neuralgia and summarize the diagnosis,treatment,and changes of clinical symptoms.CASE SUMMARY A 78-year-old male with a history of lumbar spinal stenosis was admitted to the hospital after he experienced lancinating pain around his right cheek,eyes,and lip,and was diagnosed with trigeminal neuralgia at the right maxillary and mandibular branch.He was prescribed oxcarbazepine(600 mg/d),milnacipran(25 mg/d),and oxycodone/naloxone(20 mg/10 mg/d)for four years.Four years later,the patient experienced symptoms associated with spinal stenosis,including pain in the lower extremities and unsteady gait.His serum sodium level was 127 mmol/L.Assuming oxcarbazepine to be the cause of the hyponatremia,oxcarbazepine administration was put on hold and the patient was switched to topiramate.At subsequent visit,the patient’s serum sodium level had normalized to 143 mmol/L and his unsteady gait had improved.CONCLUSION Oxcarbazepine-induced hyponatremia may cause lower extremity weakness and unsteady gait,which should be differentiated from those caused by spinal stenosis.
文摘Objective:To study effect of Oxcarbazepine on serum inflammatory factors, intercellular adhesion molecule 1(ICAM-1) and immune function in epileptic.Methods: Selected 95 patients who were diagnosed as epileptic into the observation group and 95 cases of healthy people as the control group;The observation group was given oral oxcarbazepine, continuous treatment for six months;Measured serum inflammatory factors (IL-2, IL-6, TNF-α) level, ICAM-1 and immune-related indexes: change of periphery T lymphocyte subgroup CD3+, CD4+, CD8+and immnuneglublin (IgG, IgA, IgM) level of the observation group before and after treatment, carried out comparative analysis through comparing with the normal control group.Results:Before treatment, compared with the control group, level of IL-2, IL-6, TNF-α, ICAM-1, CD8+, IgA and IgG in observation group were significantly higher than those in control group. CD3+, CD4+ level were significantly decreased when it compared with the control group. Level of IgM in the observation group was higher than that in the control group, but the difference between two groups was not significant. Before treatment, compared inter-class, level of IL-2, IL-6, TNF-α, ICAM-1, CD8+, IgA and IgG in the observation group were significantly lower, but all of these indexes level were still remarkable higher than the control group. It was statistical significant difference;After treatment, the level of CD3+, CD4+ in the observation group were dramatically increased, but both level were still significantly lower than the control group, the difference was statistically significant;Level of IgM after treatment compared with control group and before treatment respectively was no statistical significant difference.Conclusion: The level of inflammatory factors and ICAM-1 always were abnormal in epileptic and they were always with immune dysfunction. Oxcarbazepine was capable of effectively reducing inflammatory factor and ICAM-1 level and positively regulating immune dysfunction.
文摘Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May 2018 were selected as the observation group and 90 healthy volunteers were selected as control group. All patients in the observation group were treated with oxcarbazepine alone. T lymphocyte subsets, IgA, IgG, IgM, T3, T4, FT3, FT4, TSH, hs-CRP and Hcy in observation group were detected before treatment, 3 months after treatment and 6 months after treatment. The results were compared with those of the control group. Results: The levels of CD3+ and CD4+ in the control group were (65.25±9.51)% and (43.29±6.74)% respectively, which were higher than those in the observation group (P<0.05). The levels of CD8+, IgA and IgG in the control group were (22.40±6.41)%, (2.22±0.51) g/L, (9.99±1.28) g/L respectively, which were lower than those in the observation group (P<0.05). The levels of CD3+ and CD4+ in the observation group after 3 months and 6 months of treatment were significantly higher than those before treatment (P<0.05). The levels of CD8+, IgA and IgG in the observation group after 3 months and 6 months of treatment were significantly lower than those before treatment (P<0.05). There was no significant difference in the level of IgM between the observation group and the control group at each time point (P>0.05). The levels of thyroid hormones in the observation group before treatment and 3 months after treatment were not significantly different from those in the control group (P>0.05). The FT4 of the observation group was (14.98±1.03) pmol/L 6 months after treatment, which was significantly lower than that of the control group before treatment and 3 months after treatment (P<0.05). The levels of T3, T4, FT3 and TSH at each time point in the observation group were not significantly different from those in the control group (P>0.05). Before treatment, there was no significant difference in hs-CRP and Hcy levels between the observation group and the control group (P>0.05). The levels of hs-CRP and Hcy in the observation group were (4.82±0.67) mg/L and (13.36±1.51) umol/L respectively after 3 months of treatment. The levels of hs-CRP and Hcy in the observation group after 3 months of treatment were significantly higher than those before treatment and in the control group, and the difference was statistically significant (P<0.05). The levels of hs-CRP and Hcy in the observation group were (4.99±0.47) mg/L and (16.83±1.94) umol/L respectively after 6 months of treatment. The levels of hs-CRP and Hcy in the observation group were significantly higher than those in the control group after 3 months of treatment and before treatment (P<0.05). Conclusion: Oxcarbazepine can effectively improve the immune function of epilepsy patients, but with the prolongation of medication time, it may have adverse effects on thyroid function, hs-CRP and Hcy.
